Holen Sie sich die Stockscreener-App
131.28
2.40%
3.08
Handel nachbörslich:
131.28
Intra Cellular Therapies Inc Aktie (ITCI) Neueste Nachrichten
Intra-Cellular Therapies progresses in Johnson & Johnson merger By Investing.com - Investing.com Canada
Intra-Cellular Therapies progresses in Johnson & Johnson merger - Investing.com
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance
GW&K Investment Management LLC Sells 6,734 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Phocas Financial Corp. Has $241,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Equities Analysts Offer Predictions for ITCI FY2025 Earnings - MarketBeat
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 12-Month HighStill a Buy? - MarketBeat
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN
Where are the Opportunities in (ITCI) - Stock Traders Daily
Wealthspire Advisors LLC Acquires New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ING Groep NV Purchases Shares of 12,500 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Mizuho - MarketBeat
HealthInvest Partners AB Sells 13,440 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Ieq Capital LLC - MarketBeat
New York State Common Retirement Fund Has $6.40 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High of $129 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $129 - Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Alberta Investment Management Corp - MarketBeat
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc.ITCI - Business Wire
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
Needham & Company LLC Reaffirms Hold Rating for Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders - The Bakersfield Californian
Intra-Cellular Therapies Reports Strong 2024 Growth - TipRanks
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Mizuho cuts Intra-Cellular stock rating, lowers price target - Investing.com India
Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140 - Marketscreener.com
Principal Financial Group Inc. Sells 46,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 52-Week HighWhat's Next? - MarketBeat
TimesSquare Capital Management LLC Increases Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular: Q4 Earnings Snapshot - CTPost
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates - MSN
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight - GlobeNewswire
Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects - TipRanks
Intra-Cellular Therapies, Inc. SEC 10-K Report - TradingView
Form 10-K Intra-Cellular Therapies For: Dec 31 - StreetInsider.com
Intra-Cellular: Q4 Earnings Snapshot -February 21, 2025 at 08:18 am EST - Marketscreener.com
Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises -February 21, 2025 at 08:17 am EST - Marketscreener.com
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Net Loss $0.16 a Share, vs. FactSet Est of $0.07 Loss - Marketscreener.com
Intra-Cellular Therapies Reports Strong Fourth Quarter 2024 Results with 51% Increase in CAPLYTA Net Sales and FDA Review Acceptance for New Indication - Nasdaq
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Revenue $199.2M, vs. FactSet Est of $193.4M - Marketscreener.com
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire Inc.
Savant Capital LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Update - MarketBeat
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat - MSN
StockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC - MarketBeat
3.57%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):